CATALENT INC.

ISIN: US1488061029 WKN: 148806102 Asset Class: Stock



Company Profile

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Financial figures, Fiscal year: from 01.07. to 30.06.

| | 20 | 23 | 20 | 22 | 202 | 21 |
|--------------------------------|----------------|------------------------|----------------|------------------------|---------------|------------------------|
| Financial figures | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets I | _iabilities and equity |
| Current assets | 2,692,000,000 | | 2,916,000,000 | | 2,918,000,000 | |
| Common stock capital | | 2,000,000 | | 2,000,000 | | 2,000,000 |
| Fixed assets | 8,085,000,000 | | 7,591,000,000 | | 6,194,000,000 | |
| Equity capital of a company | | 4,611,000,000 | | 4,795,000,000 | | 4,274,000,000 |
| Cash and cash equivalents | 280,000,000 | | 449,000,000 | | 896,000,000 | |
| Accrued liabilities | | 100,000,000 | | 103,000,000 | | 137,000,000 |
| Other assets | - | | - | | - | |
| Current liabilities | | 1,530,000,000 | | 1,072,000,000 | | 1,196,000,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 4,636,000,000 | | 4,640,000,000 | | 3,642,000,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 92,000,000 | | 79,000,000 | | 102,000,000 |
| Total assets | 10,777,000,000 | 10,777,000,000 | 10,507,000,000 | 10,507,000,000 | 9,112,000,000 | 9,112,000,000 |

| Dalarioo riotoo | | | |
|---------------------|---------|---------|---------|
| | 2023 | 2022 | 2021 |
| Accounting standard | US-GAAP | US-GAAP | US-GAAP |
| Employees | 17,800 | 19,000 | 17,300 |
| Equity ratio | 42.79% | 45.64% | 46.91% |
| Debt-equity ratio | 133.72% | 119.12% | 113.20% |

| Others | | | |
|------------------|--------|--------|--------|
| | 2023 | 2022 | 2021 |
| Tax Expense Rate | 25.15% | 14.21% | 18.18% |

Balance notes

CATALENT INC.

ISIN: US1488061029 WKN: 148806102 Asset Class: Stock

| Income statement | | | |
|--|---------------|---------------|---------------|
| | 2023 | 2022 | 2021 |
| Turnover | 4,263,000,000 | 4,828,000,000 | 3,998,000,000 |
| Net income | -256,000,000 | 503,000,000 | 529,000,000 |
| EBIT | -141,882,000 | 662,116,000 | 750,337,500 |
| Operating income before taxes | -342,000,000 | 605,000,000 | 715,000,000 |
| Cash Flow | 254,000,000 | 439,000,000 | 433,000,000 |
| Net interest income | -186,000,000 | -123,000,000 | -110,000,000 |
| Research and development expenses | 18,000,000 | 23,000,000 | 21,000,000 |
| Income taxes | -86,000,000 | 86,000,000 | 130,000,000 |
| Result from investments in subsidaries, associates and other | 0 | 0 | 0 |
| Revenues per employee | 217,820 | 231,109 | 210,184 |

Board of Directors

| Members of Management Board | | |
|-----------------------------|--------------------------------|--|
| John Greisch | Chairman of Board of Directors | |
| Donald Morel | Member of Board of Directors | |
| Frank D'Amelio | Member of Board of Directors | |
| Gregory Lucier | Member of Board of Directors | |
| J. Carroll | Member of Board of Directors | |
| Jack Stahl | Member of Board of Directors | |
| Michael Barber | Member of Board of Directors | |
| Michelle Ryan | Member of Board of Directors | |
| Rolf Classon | Member of Board of Directors | |
| Stephanie Okey | Member of Board of Directors | |
| Steven Barg | Member of Board of Directors | |
| Alessandro Maselli | Chairman of Managing Board | |
| Charles Lickfold | Member of Executive Committee | |
| Joseph A. Ferraro | Member of Executive Committee | |
| Karen Santiago | Member of Executive Committee | |
| Lisa Evoli | Member of Executive Committee | |
| Matti Masanovich | Member of Executive Committee | |
| Ricky Hopson | Member of Executive Committee | |